Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

TSX:EDT - Post Discussion

Spectral Medical Inc > An Interview With Baxter On Sepsis
View:
Post by Revten on Feb 09, 2024 7:16pm

An Interview With Baxter On Sepsis

Good Read!

Wonder if Baxter will make History With PMX?

https://www.baxter.com/perspectives/healthcare-insights/treating-sepsis-clinicians-perspective
 

I Think So!
 

Great Weekly Close  At .63 Cents. 

Have A Great Weekend!

Rev

Comment by daviking on Feb 09, 2024 8:13pm
Hmm, when was this interview done? ?????? No comment regarding PMX  or EAA.  Definitely a "life threatening condition" but nothing we didn't know before
Comment by hmmmmmmmm on Feb 09, 2024 10:02pm
The article states: "You were an investigator in a recently-published randomized clinical trial" -that trial was published May 6th 2020. So the article looks to be 3+ years old. 
Comment by mercedesman on Feb 10, 2024 8:52am
Nevertheless this confirms that Baxter has a keen interest in solving the Sepsis dilemma. Which is also demonstrated by the fact that they own Oxiris, a hemopurfusion filter that removes inflammatory mediators. However this product has had only mixed success in the past and currently has no FDA trial underway.  Surely they would be keenly interested in a FDA approved filter that is proven ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities